Is the price fair?
What JNJ's price assumes
Johnson & Johnson trades at 31.3× earnings against 27.4× for the median Drug Manufacturers - General name, more expensive than its own group.
31.3
Trailing P/E · Drug Manufacturers - General median 27.4 · 1.14× the median: the market pays up for this one
- Price / sales
- 6.07
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.0%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- +8.5%
Growth the price implies · The price pays for +8.5% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.
Details›
- Price / book2026-Q1
- 7.20
- EV / sales2026-Q1
- 6.23
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $22.2B
- Market capitalisation
- $549.8B
- 3-year revenue growth
- +5.9%
- 3-year free cash flow growth
- +15%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $164.14 |
| Its own P/E history, median | $178.77 |
| Its own P/E history, upper quartile | $199.10 |
| 52-week range | $167.35 – $273.40 |
| Today | $270.09 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #2 of 16 by Smart Score